Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Schedule of Revenue by Major Customers

		Three Months Ended June 30,				Six Months Ended June 30,
Licensee	Product Name	2014		2013		2014		2013
Genentech	Avastin®	24	%	31	%	27	%	33	%
	Herceptin®	24	%	32	%	25	%	32	%
	Lucentis®	10	%	20	%	11	%	17	%
Biogen Idec1	Tysabri®	8	%	9	%	9	%	11	%
Depomed	Glumetza®	16	%	0	%	13	%	0	%